Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma

Ashutosh D. Wechalekar, C. I. Chen, D. Sutton, D. Reece, M. Voralia, A. K. Stewart

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

Thalidomide at doses >200 mg has 100% grade 1-2 and 25% grade 3-4 toxicities requiring discontinuation. We report a retrospective study of relapsed myeloma patients treated with thalidomide 200 mg with no dose escalation. Thirty patients were identified; 43% of patients responded with paraprotein decline >75% - 2 (6%), 50-75% - 7 (23%), 25-50% - 4 (14%) and 2 (6%) were stable. All five patients with 13q deletion responded. Only 54% reported grade 1-2 toxicities (none reporting > grade 2) with 5 (17%) discontinuing treatment due to toxicity. Thalidomide 200 mg daily with no dose escalation appears as effective and better tolerated than escalated doses for relapsed myeloma patients.

Original languageEnglish (US)
Pages (from-to)1147-1149
Number of pages3
JournalLeukemia and Lymphoma
Volume44
Issue number7
DOIs
StatePublished - Jul 1 2003

    Fingerprint

Keywords

  • Dose escalation
  • Efficacy
  • Intermediate dose
  • Thalidomide

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this